EP3441392A1 — A pharmaceutical composition for oral administration
Assigned to Intellikine LLC · Expires 2019-02-13 · 7y expired
What this patent protects
A pharmaceutical composition for oral administration comprising an effective amount of a compound of Formula V-A2: or a pharmaceutically acceptable salt thereof; wherein B is a moiety of Formula II: W c is aryl, heteroaryl, heterocycloalkyl, or cycloalkyl; q is an …
USPTO Abstract
A pharmaceutical composition for oral administration comprising an effective amount of a compound of Formula V-A2: or a pharmaceutically acceptable salt thereof; wherein B is a moiety of Formula II: W c is aryl, heteroaryl, heterocycloalkyl, or cycloalkyl; q is an integer of 0 or 1; R 1 is hydrogen, alkyl, or halo; R 2 is alkyl or halo; R 3 is halo; and R 9 is alkyl, or heterocycloalkyl; and one or more pharmaceutically acceptable excipients suitable for oral administration. The pharmaceutical composition may contain an effective amount of a second agent such as a chemotherapeutic agent, e.g. a proteasome inhibitor, an alkylating agent or a therapeutic antibody.
Drugs covered by this patent
- Copiktra (DUVELISIB) · Secura
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.